File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes

TitleCirculating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes
Authors
Issue Date2021
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
Citation
Diabetes Care, 2021, v. 44 n. 9, p. 2089-2097 How to Cite?
AbstractOBJECTIVE Preclinical studies have suggested that thrombospondin-2 (TSP2) is implicated in liver fibrosis. However, the clinical relevance of TSP2 in nonalcoholic fatty liver disease (NAFLD) remains undefined. Here, we investigated the cross-sectional and longitudinal associations of circulating TSP2 levels with advanced fibrosis (F3 or greater [≥FE] fibrosis) in NAFLD. RESEARCH DESIGN AND METHODS Serum TSP2 levels were measured in 820 patients with type 2 diabetes and NAFLD. All participants received vibration-controlled transient elastography (VCTE) at baseline to evaluate their hepatic steatosis and fibrosis using controlled attenuation parameter (CAP) and liver stiffness (LS) measurements, respectively. Among those without advanced fibrosis at baseline, reassessment VCTE was performed to determine whether ≥F3 fibrosis had developed over time. Multivariable logistic regression analysis was used to evaluate the cross-sectional and longitudinal associations of serum TSP2 level with ≥F3 fibrosis. RESULTS Baseline serum TSP2 level was independently associated with the presence of ≥F3 fibrosis (odds ratio [OR] 5.13, P < 0.001). The inclusion of serum TSP2 level significantly improved the identification of ≥F3 fibrosis by clinical risk factors. Over a median follow-up of 1.5 years, 8.8% developed ≥F3 fibrosis. Baseline serum TSP2 level was significantly associated with incident ≥F3 fibrosis (OR 2.82, P = 0.005), independent of other significant clinical risk factors of fibrosis progression, including BMI, platelet count, and CAP at baseline. CONCLUSIONS Circulating TSP2 level was associated with both the presence and the development of advanced fibrosis and might be a potentially useful prognostic biomarker for the development and progression of liver fibrosis in patients with type 2 diabetes and NAFLD.
Persistent Identifierhttp://hdl.handle.net/10722/309101
ISSN
2023 Impact Factor: 14.8
2023 SCImago Journal Rankings: 5.694
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, CH-
dc.contributor.authorSeto, WK-
dc.contributor.authorLui, DTW-
dc.contributor.authorFong, CHY-
dc.contributor.authorWan, HY-
dc.contributor.authorCheung, CYY-
dc.contributor.authorChow, WS-
dc.contributor.authorWoo, YC-
dc.contributor.authorYuen, MF-
dc.contributor.authorXu, A-
dc.contributor.authorLam, KSL-
dc.date.accessioned2021-12-14T01:40:35Z-
dc.date.available2021-12-14T01:40:35Z-
dc.date.issued2021-
dc.identifier.citationDiabetes Care, 2021, v. 44 n. 9, p. 2089-2097-
dc.identifier.issn0149-5992-
dc.identifier.urihttp://hdl.handle.net/10722/309101-
dc.description.abstractOBJECTIVE Preclinical studies have suggested that thrombospondin-2 (TSP2) is implicated in liver fibrosis. However, the clinical relevance of TSP2 in nonalcoholic fatty liver disease (NAFLD) remains undefined. Here, we investigated the cross-sectional and longitudinal associations of circulating TSP2 levels with advanced fibrosis (F3 or greater [≥FE] fibrosis) in NAFLD. RESEARCH DESIGN AND METHODS Serum TSP2 levels were measured in 820 patients with type 2 diabetes and NAFLD. All participants received vibration-controlled transient elastography (VCTE) at baseline to evaluate their hepatic steatosis and fibrosis using controlled attenuation parameter (CAP) and liver stiffness (LS) measurements, respectively. Among those without advanced fibrosis at baseline, reassessment VCTE was performed to determine whether ≥F3 fibrosis had developed over time. Multivariable logistic regression analysis was used to evaluate the cross-sectional and longitudinal associations of serum TSP2 level with ≥F3 fibrosis. RESULTS Baseline serum TSP2 level was independently associated with the presence of ≥F3 fibrosis (odds ratio [OR] 5.13, P < 0.001). The inclusion of serum TSP2 level significantly improved the identification of ≥F3 fibrosis by clinical risk factors. Over a median follow-up of 1.5 years, 8.8% developed ≥F3 fibrosis. Baseline serum TSP2 level was significantly associated with incident ≥F3 fibrosis (OR 2.82, P = 0.005), independent of other significant clinical risk factors of fibrosis progression, including BMI, platelet count, and CAP at baseline. CONCLUSIONS Circulating TSP2 level was associated with both the presence and the development of advanced fibrosis and might be a potentially useful prognostic biomarker for the development and progression of liver fibrosis in patients with type 2 diabetes and NAFLD.-
dc.languageeng-
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/-
dc.relation.ispartofDiabetes Care-
dc.rightsThis is an author-created, uncopyedited electronic version of an article accepted for publication in TITLE [Journal URL]. The American Diabetes Association (ADA), publisher of TITLE, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version is available online at [URL]-
dc.titleCirculating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes-
dc.typeArticle-
dc.identifier.emailLee, CH: pchlee@hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailLui, DTW: dtwlui@hku.hk-
dc.identifier.emailFong, CHY: kalofong@hku.hk-
dc.identifier.emailCheung, CYY: cyy0219@hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.emailXu, A: amxu@hkucc.hku.hk-
dc.identifier.emailLam, KSL: ksllam@hku.hk-
dc.identifier.authorityLee, CH=rp02043-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityLui, DTW=rp02803-
dc.identifier.authorityCheung, CYY=rp02243-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.authorityXu, A=rp00485-
dc.identifier.authorityLam, KSL=rp00343-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2337/dc21-0131-
dc.identifier.pmid34183428-
dc.identifier.scopuseid_2-s2.0-85115450004-
dc.identifier.hkuros331025-
dc.identifier.volume44-
dc.identifier.issue9-
dc.identifier.spage2089-
dc.identifier.epage2097-
dc.identifier.isiWOS:000711167300029-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats